These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 31464648)

  • 1. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Mahajan UM; Langhoff E; Goni E; Costello E; Greenhalf W; Halloran C; Ormanns S; Kruger S; Boeck S; Ribback S; Beyer G; Dombroswki F; Weiss FU; Neoptolemos JP; Werner J; D'Haese JG; Bazhin A; Peterhansl J; Pichlmeier S; Büchler MW; Kleeff J; Ganeh P; Sendler M; Palmer DH; Kohlmann T; Rad R; Regel I; Lerch MM; Mayerle J
    Gastroenterology; 2018 Nov; 155(5):1625-1639.e2. PubMed ID: 30092175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.
    Kiryu S; Ito Z; Suka M; Bito T; Kan S; Uchiyama K; Saruta M; Hata T; Takano Y; Fujioka S; Misawa T; Yamauchi T; Yanagisawa H; Sato N; Ohkusa T; Sugiyama H; Koido S
    BMC Cancer; 2021 Nov; 21(1):1197. PubMed ID: 34758773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
    Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
    World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma.
    Chen X; Yu S; Chen J; Chen X
    Cancer Immunol Immunother; 2024 Jun; 73(8):149. PubMed ID: 38833018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
    Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
    World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma.
    Gong R; Wang J; Xing Y; Wang J; Chen X; Lei K; Yu Q; Zhao C; Li S; Zhang Y; Wang H; Ren H
    Cancer Lett; 2024 May; 590():216838. PubMed ID: 38561039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
    Jamieson NB; Morran DC; Morton JP; Ali A; Dickson EJ; Carter CR; Sansom OJ; Evans TR; McKay CJ; Oien KA
    Clin Cancer Res; 2012 Jan; 18(2):534-45. PubMed ID: 22114136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel prognostic factor TIPE2 inhibits cell proliferation and promotes apoptosis in pancreatic ductal adenocarcinoma (PDAC).
    Sun Y; Cao S; Li Z; Liu X; Xu J; Tian Y; Shen S; Zhou Y
    Int J Med Sci; 2021; 18(9):2051-2062. PubMed ID: 33850476
    [No Abstract]   [Full Text] [Related]  

  • 10. Unraveling pancreatic ductal adenocarcinoma immune prognostic signature through a naive B cell gene set.
    Zhang S; Ta N; Zhang S; Li S; Zhu X; Kong L; Gong X; Guo M; Liu Y
    Cancer Lett; 2024 Jul; 594():216981. PubMed ID: 38795761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
    Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
    Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer survival analysis defines a signature that predicts outcome.
    Raman P; Maddipati R; Lim KH; Tozeren A
    PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection.
    Drifka CR; Loeffler AG; Mathewson K; Keikhosravi A; Eickhoff JC; Liu Y; Weber SM; Kao WJ; Eliceiri KW
    Oncotarget; 2016 Nov; 7(46):76197-76213. PubMed ID: 27776346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery.
    Sergeant G; van Eijsden R; Roskams T; Van Duppen V; Topal B
    BMC Cancer; 2012 Nov; 12():527. PubMed ID: 23157946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics.
    Cysneiros MAPC; Cirqueira MB; Barbosa LF; Chaves de Oliveira Ê; Morais LK; Wastowski IJ; Floriano VG
    PLoS One; 2024; 19(7):e0305648. PubMed ID: 38954689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.
    Askan G; Sahin IH; Chou JF; Yavas A; Capanu M; Iacobuzio-Donahue CA; Basturk O; O'Reilly EM
    BMC Cancer; 2021 Apr; 21(1):385. PubMed ID: 33836674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.
    Denley SM; Jamieson NB; McCall P; Oien KA; Morton JP; Carter CR; Edwards J; McKay CJ
    J Gastrointest Surg; 2013 May; 17(5):887-98. PubMed ID: 23435739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma.
    Sun X; Song H; Sun X; Liao C; Wang G; Xu Y; Li L; Han Y; Xu C; Wang W; Cai S; Liang H; Yu H
    Cancer Invest; 2024 Mar; 42(3):226-242. PubMed ID: 38616304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual and triple gene combinations of KRT5, KRT17, and S100A2 identify basal-like subtype of pancreatic ductal adenocarcinoma and correlate with survival outcome.
    Chen Q; Chen Z; Zhang J; Cai Y; Wu S; He D; Cheng K; Gu X; Cai Y; Wang X; Li Y; Zhang M; Wu Z; Peng B
    FASEB J; 2024 Aug; 38(15):e23867. PubMed ID: 39101950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AHNAK2 is a potential prognostic biomarker in patients with PDAC.
    Lu D; Wang J; Shi X; Yue B; Hao J
    Oncotarget; 2017 May; 8(19):31775-31784. PubMed ID: 28423668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.